Adult Dosing

Active Duodenal Ulcer

• 300 mg PO qhs; alt: 150 mg PO bid

Maintenance of Healed Duodenal Ulcer

• 150 mg PO qhs

Gastroesophageal reflux (GERD)

• 150 mg PO bid

Active Benign Gastric Ulcer

• Recommended dose: 300 mg PO qhs; alt 150 mg PO bid

Treatment or prevention of heartburn (OTC product only)

• 75 mg PO PRN, 30-60 min before meals
• Max 150 mg/day

Pediatric Dosing

Gastroesophageal reflux (GERD)

• 12 yrs: 150 mg PO (oral soln) bid
• Max: 300 mg/d PO qd x 8 wks

Esophagitis

• 12 yrs: 150 mg PO (oral soln) bid
• Max: 300 mg/d PO qd x 8 wks

[Outline]

• Adult Dosing
• Pediatric Dosing

• Treatment for up to 8 weeks in patients with active duodenal ulcer and active benign gastric ulcers
• Maintenance therapy for duodenal ulcer after healing of active duodenal ulcer
• Treatment for up to 12 weeks in endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD

• Hypersensitivity to any of the ingredients of the product
• Hx of hypersensitivity to H2 receptor antagonists

• N/A

Renal Dose Adjustment (Based on CrCl):

Active duodenal ulcer/gastric ulcer, GERD

• 20-50 mL/min: 150 mg PO qd
• <20 mL/min: 150 mg PO every other day

Maintenance therapy

• 20-50 mL/min: 150 mg PO every other day
• <20 mL/min: 150 mg PO every 3 days

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustment not defined

• Symptomatic response to nizatidine does not prevent the presence of gastric malignancy
• Consider reduction of dose in patients with moderate to severe renal impairment, as this drug is excreted primarily by the kidney

Caution: Use cautiously in

• Renal impairment

Axid, Axid AR interacts with :

	Acalabrutinib
	Atazanavir
	Bosulif
	Bosutinib
	Calquence
	Cefditoren
	Cefpodoxime
	Ceftin
	Cefuroxime
	CellCept
	Crixivan
	Crizotinib
	Dabrafenib
	Dasatinib
	DiaBeta
	Edurant
	Erlotinib
	Extina
	Gefitinib
	Glipizide
	Glucotrol
	Glucotrol XL
	Glucovance
	Glyburide
	Glynase
	Harvoni
	Indinavir
	Iressa
	Itraconazole
	Ketoconazole
	Lapatinib
	Ledipasvir
	Mycophenolate
	Myfortic
	Nelfinavir
	Neratinib
	Nerlynx
	Nexavar
	Nizoral
	Nizoral A-D Shampoo
	Nizoral Shampoo
	Noxafil
	Onmel
	Posaconazole
	Reyataz
	Rilpivirine
	Sorafenib
	Spectracef
	Sporanox
	Sprycel
	Tafinlar
	Tarceva
	Tykerb
	Vantin
	Viracept
	Xalkori
	Xolegel
	Zinacef

Pregnancy Category:B

Breastfeeding: Excreted in breastmilk in low levels; unlikely to adversely affect the breastfed infant. Histamine H2-antagonists with more extensive use might be preferred in newborns. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 3 June 2011). As per manufacturer data, 0.1% of the administered oral dose of nizatidine is secreted in human milk in proportion to plasma concentrations; decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

• CV: Chest pain
• CNS: Headache, asthenia, insomnia, somnolence
• PSYCHIATRY: Abnormal dreams, anxiety
• GI: Abdominal pain, diarrhea, nausea, flatulence, vomiting, dyspepsia, constipation, dry mouth
• GU: Impotence
• HEMA: Anemia, thrombocytopenia
• METABOLIC: Hyperuricemia
• DERM: Rash, pruritis, sweating, urticaria
• RESP: Rhinitis, pharyngitis, sinusitis, increased cough, exfoliative dermatitis
• HEPA: Hepatocellular injury, elevated LFTs
• MUSC: Back pain, myalgia
• MISC: Pain, infection, fever

• Histamine H2 antagonist; reversibly and competitively blocks histamine at H2 receptors on the on the gastric basolateral membrane of parietal cells, leading to inhibition of gastric acid secretion
• Absorbed 70% following oral administration
• Metabolized by liver; CYP450: unknown
• Excreted in urine >90% (60% unchanged) and in feces <6%
• Half-life: 1-2 hrs; 3.5-11 hrs (anephric patients)

US Trade Name(s)

• Axid
• Axid AR

US Availability

nizatidine (generic)

• CAPS: 150, 300 mg
• SOLN: 15 mg/mL

Axid

• CAPS: 150, 300 mg
• SOLN: 15 mg/mL

Axid-AR

• TABS: 75 mg

Canadian Trade Name(s)

• Axid

Canadian Availability

nizatidine (generic)

• CAPS: 150, 300 mg

Axid

• CAPS: 150, 300 mg

UK Trade Name(s)

• Axid

UK Availability

Axid

• CAPS: 150, 300 mg

Australian Trade Name(s)

• Nizac
• Tacidine
• Tazac

Australian Availability

Nizac, Tacidine, Tazac

• CAPS: 150, 300 mg

[Outline]

Gastrointestinal

Antiulcer Agents

Histamine H2 Antagonists

Pricing data from www.DrugStore.com in U.S.A.

• Axid 300 MG CAPS [Bottle] (GLAXO SMITH KLINE)
  30 mg = $169.98
  90 mg = $489.97
• Nizatidine 15 MG/ML SOLN [Bottle] (AMNEAL PHARMACEUTICALS)
  473 ml = $272
  1419 ml = $795.98
• Nizatidine 300 MG CAPS [Bottle] (MYLAN)
  30 mg = $54
  90 mg = $138.97
• Axid 15 MG/ML SOLN [Bottle] (BRAINTREE LAB)
  480 ml = $409.84
  1440 ml = $1120.25
• Axid 150 MG CAPS [Bottle] (GLAXO SMITH KLINE)
  60 mg = $172.98
  180 mg = $499.87
• Nizatidine 150 MG CAPS [Bottle] (DR.REDDY'S LABORATORIES)
  INC. mg = $60
  mg = $180

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.

• Axid AR 75 MG Oral Tablet (Wyeth Consumer Healthcare)
• Nizatidine 150 MG Oral Capsule (Dr Reddy's Laboratories Limited)
• Nizatidine 150 MG Oral Capsule (Genpharm Inc.)
• Nizatidine 150 MG Oral Capsule (Mylan Pharmaceuticals Inc.)
• Nizatidine 150 MG Oral Capsule (Sandoz, Inc.)
• Nizatidine 150 MG Oral Capsule (Teva Pharmaceuticals USA)
• Nizatidine 150 MG Oral Capsule (nizatidine)
• Nizatidine 300 MG Oral Capsule (Dispensing Solutions Inc.)
• Nizatidine 300 MG Oral Capsule (Dr Reddy's Laboratories Limited)
• Nizatidine 300 MG Oral Capsule (Genpharm Inc.)
• Nizatidine 300 MG Oral Capsule (Mylan Pharmaceuticals Inc.)
• Nizatidine 300 MG Oral Capsule (Sandoz, Inc.)
• Nizatidine 300 MG Oral Capsule (Teva Pharmaceuticals USA)